Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or withoutbevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ)adenocarcinoma

A Okines, Ruth Langely, LC Thompson, SP Stenning, L Stevenson, S Falk, MT Seymour, FY Coxon, Gary Middleton, D Smith, L Evans, S Slater, JS Water, D Ford, M Hall, Tim Iveson, Russell David Petty, C Plummer, W Alum, David Cunningham

Research output: Contribution to journalArticle

Original languageEnglish
Article number4092
JournalJournal of Clinical Oncology
Volume29
Issue numberSuppl.
Publication statusPublished - 2011

Cite this

Okines, A., Langely, R., Thompson, LC., Stenning, SP., Stevenson, L., Falk, S., Seymour, MT., Coxon, FY., Middleton, G., Smith, D., Evans, L., Slater, S., Water, JS., Ford, D., Hall, M., Iveson, T., Petty, R. D., Plummer, C., Alum, W., & Cunningham, D. (2011). Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or withoutbevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ)adenocarcinoma. Journal of Clinical Oncology, 29(Suppl.), [4092].